Given the aforementioned, highly specific unmet clinical need for a relatively small ratio of patients with prostate cancer undergoing PSMA imaging, our proposed acquisition protocol mandates a well-balanced preselection of patients. This evidence concerns the gene FOLH1 and prostate cancer.